Krystal Biotech (KRYS) Cash & Equivalents (2016 - 2026)

Krystal Biotech has disclosed Cash & Equivalents across 11 years of filings, most recently posting $501.3 million for Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $501.3 million, up 62.36% year-over-year; the trailing twelve-month figure through Mar 2026 was $501.3 million (up 62.36% YoY), and the FY2025 annual result was $496.3 million, up 43.91% from the prior year.
• Cash & Equivalents came in at $501.3 million for Q1 2026 at Krystal Biotech, up from $496.3 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $501.3 million in Q1 2026 to a low of $140.7 million in Q1 2023.
• The 5-year median for Cash & Equivalents is $345.8 million (2024), against an average of $321.2 million.
• Across the five-year window, Cash & Equivalents sank 52.56% in 2022 and surged 155.08% in 2024, its largest moves.
• Krystal Biotech's Cash & Equivalents stood at $161.9 million in 2022, then soared by 121.33% to $358.3 million in 2023, then declined by 3.76% to $344.9 million in 2024, then jumped by 43.91% to $496.3 million in 2025, then advanced by 1.01% to $501.3 million in 2026.
• The last three Cash & Equivalents figures came in at $501.3 million (Q1 2026), $496.3 million (Q4 2025), and $392.6 million (Q3 2025), per Business Quant data.